Is IDEXX Laboratories, Inc. (IDXX) Overvalued?
We dive into why IDEXX Laboratories, Inc. (IDXX) could be considered overvalued on 2026-07-16, based on AAII’s Value Score and Grade.Rosalio Madrigal
Stock Evaluator: IDEXX Laboratories, Inc. (IDXX)
IDEXX Laboratories, Inc. IDXX
$559.07
0.27
0.05%
July 31, 2026 4:00:00 PM
EST
Volume: 630,768
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Commentary & Analysis
What You Need to Know About IDEXX Laboratories, Inc.'s Q2 Earnings
IDEXX Laboratories, Inc.'s fiscal Q2 earnings report was released on Tuesday, May 05. Let's dive in to see if (IDXX) missed or beat analyst's expectations.Tudor Pop
Which Is a Better Investment, IDEXX Laboratories, Inc. or Solventum Corporation Stock?
Learn more about whether IDEXX Laboratories, Inc. or Solventum Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Why IDEXX Laboratories, Inc.’s (IDXX) Stock Is Down 5.76%
As of Monday, February 02, IDEXX Laboratories, Inc.’s IDXX share price has dipped by 5.76%, which has investors questioning if this is right time to buy.Jenna Brashear
What You Need to Know About IDEXX Laboratories, Inc.'s Q1 Earnings
IDEXX Laboratories, Inc.'s fiscal Q1 earnings report was released on Monday, February 02. Let's dive in to see if (IDXX) missed or beat analyst's expectations.Omar Beirat
Financial Summary
| Share Statistics | IDXX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $44,101.1 | $337.2 | 93% |
|
| Shares Out (Mil) | 80.2 | 41.9 | 58% |
|
| Institutional Ownership | 99.7% | 77.8% | 93% |
|
| Float (Mil) | 78.6 | 34.7 | 57% |
|
| Beta | 1.54 | 0.85 | 83% |
|
| Avg Daily Volume (000s) | 477 | 278 | 58% |
|
| Price Change (52-week) |
(2.3%) | 58.7% | 43% |
|
| Growth | IDXX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 9.7% | 11.8% | 57% |
|
| Net Income (5yr) | 12.7% | (5.8%) | 59% |
|
| EPS (5yr) | 14.3% | 11.4% | 54 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (19.1%) | (16.3%) | 35% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 14 | 14 | |
| Current EPS | $3.934 | $14.623 | $16.517 | |
| Month Ago EPS | $3.941 | $14.625 | $16.516 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $3.924 | $14.509 | $16.398 | |
| Year/Year Chg | 13.4% | 11.8% | 42.9% | |
| Financials | IDXX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4,446 | $152 | 73% |
|
| Net Income (TTM) (Mil) | $1,095 | ($10) | 87% |
|
| EPS (TTM) | $13.689 | ($0.500) | 97% |
|
| Operating Cash Flow (TTM) (Mil) | $1,210 | ($2) | 83% |
|
| Net Cash Flow (TTM) (Mil) | $37 | $1 | 68% |
|
| Long-Term Debt (Q1) (Mil) | $399 | $22 | 57% |
|
| Enterprise Value (Q1) (Mil) | $44,409 | $304 | 91% |
|
| Valuation | IDXX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 28.47 | 2.80 | 97% |
|
| P/E | 41.1 | 31.1 | 79% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 2.9 | 1.9 | 77% |
|
| Ratios | IDXX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 62.1% | 59.1% | 75% |
|
| Net Margin | 24.6% | (7.3%) | 84% |
|
| ROA | 33.2% | (13.7%) | 99% |
|
| ROE | 72.9% | (15.8%) | 95% |
|
| Liabilities to Assets | 54.0% | 44.7% | 46% |
|
| F-Score | 8 | 4 | 94% |
|
IDEXX Laboratories, Inc. did not pass any screens on 7/31/2026.
